Regranex becaplermin: CHIR said preliminary Phase III data show favorable results, to be reported in the future. Plans for supplying adequate amounts of the pro

Chiron Corp. (CHIR), Emeryville, Calif. Product: Regranex becaplermin, containing recombinant human platelet-derived growth factor Indication: Wound healing Status: CHIR said preliminary Phase III da...